Adaptive Biotechnologies 경영진
경영진 기준 점검 2/4
Adaptive Biotechnologies CEO는 Chad Robins, Sep2009 에 임명되었습니다 의 임기는 16.67 년입니다. 총 연간 보상은 $9.08M, 7.7% 급여 및 92.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $21.23M 가치에 해당하는 회사 주식의 0.95% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 7.6 년과 12.4 년입니다.
핵심 정보
Chad Robins
최고경영자
US$9.1m
총 보수
| CEO 급여 비율 | 7.69% |
| CEO 재임 기간 | 16.7yrs |
| CEO 지분 보유율 | 1.0% |
| 경영진 평균 재임 기간 | 7.6yrs |
| 이사회 평균 재임 기간 | 12.4yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 17
ADPT: 2026 MRD Execution And Margin Discipline Will Support Future Upside Potential
Analysts now see Adaptive Biotechnologies' fair value edging from $20.57 to $20.14, reflecting mixed price target revisions. One firm cut its target by $3, while another raised its target by $2, as they update assumptions around growth, margins, the discount rate and future P/E expectations.내러티브 업데이트 • May 01
ADPT: 2026 MRD Outlook And Margin Discipline Will Drive Future Upside Potential
The updated analyst price target for Adaptive Biotechnologies moves slightly lower to about $20.57 from $20.86. Analysts attribute this change to modest adjustments to fair value estimates, discount rate assumptions, and longer term profit margin and P/E expectations.
내러티브 업데이트 • Apr 16
ADPT: MRD Revenue Outlook And Refreshed Models Will Support Future Cash Flows
Narrative Update on Adaptive Biotechnologies The consensus analyst price target for Adaptive Biotechnologies has moved up by $1, reflecting updated analyst models that incorporate adjusted discount rates, refreshed revenue growth and profit margin assumptions, and a revised, still very large forward P/E framework. Analyst Commentary Recent Street research on Adaptive Biotechnologies centers on modestly higher price targets, with several bullish analysts revising their models at roughly the same time.내러티브 업데이트 • Apr 02
ADPT: MRD 2026 Outlook And Discount Assumptions Will Support Future Upside Potential
Analysts have raised their price targets on Adaptive Biotechnologies by about $1, reflecting updated views on discount rates, growth, margins, and future P/E assumptions. These changes keep the stock's fair value estimate effectively unchanged at around $21.내러티브 업데이트 • Mar 19
ADPT: MRD Outlook And Pfizer Agreements Will Support Future Cash Flows
Analysts have inched their average price targets on Adaptive Biotechnologies higher, often by about $1 increments. These changes reflect updated views that modestly adjust revenue growth, profit margin and future P/E assumptions while keeping the fair value estimate near $22.내러티브 업데이트 • Mar 04
ADPT: MRD And Pfizer Agreements Will Support Future Cash Flow Upside
The analyst price target for Adaptive Biotechnologies has shifted from $21.00 to $22.00. Analysts point to updated assumptions around growth, profitability, and long-term P/E expectations following a series of recent target increases across the Street.내러티브 업데이트 • Feb 18
ADPT: Pfizer Agreements And MRD Progress Will Support Future Upside Potential
Analysts have nudged their average price target for Adaptive Biotechnologies higher by about $1, reflecting updated fair value assumptions and slightly revised views on growth, margins and future P/E, in line with recent target increases from several research firms. Analyst Commentary Recent research updates cluster around modest target increases and a generally supportive view of Adaptive Biotechnologies, with most of the focus on refreshed fair value work rather than sweeping changes to the thesis.내러티브 업데이트 • Feb 03
ADPT: Sector Tailwinds And Pfizer Partnerships Will Support Measured Future Upside
Analysts have nudged their price targets on Adaptive Biotechnologies slightly higher, with Street research pointing to target increases such as TD Cowen moving to $20 from $19. This contributes to a modest lift in our fair value estimate from $20.00 to about $20.14 as they highlight solid expected sector results and fundamentals.내러티브 업데이트 • Jan 20
ADPT: Sector Tailwinds And Cancer Testing Leadership Will Support Future Upside
Narrative Update: Adaptive Biotechnologies The analyst price target for Adaptive Biotechnologies has moved from $19 to $20, reflecting updated views that incorporate recent Q4 preview work on diagnostics peers, expectations for solid sector results and 2026 outlooks, and the company’s latest Q3 report. Analyst Commentary Recent Street research around Adaptive Biotechnologies has focused on updated price targets that reflect fresh sector work and the company’s latest Q3 report.내러티브 업데이트 • Jan 05
ADPT: MRD Platform And Pfizer Agreements Will Support Long-Term Cash Flow Upside
Analysts have lifted their price target on Adaptive Biotechnologies to $16 from $11, citing the recent Q3 report as the key driver behind this updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the new US$16 price target, up from US$11, as a sign that expectations for execution and risk reward have shifted in a more constructive direction after the recent Q3 report.Seeking Alpha • Dec 26
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle
Summary Adaptive Biotechnologies Corporation maintains a Hold rating as MRD segment momentum is offset by competitive and valuation concerns. ADPT's Q3 top-line strength was driven by a one-time Genentech payment; ex-Genentech, MRD revenue grew 52% Y/Y, showing underlying operational progress. MRD segment achieved standalone cash flow positivity, but consolidated profitability remains elusive without normalization; FY25 MRD guidance was raised. DLBCL market share defense and workflow integration are critical as competition intensifies, making 2026 a pivotal "prove it" year for ADPT. Read the full article on Seeking Alpha내러티브 업데이트 • Dec 15
ADPT: MRD Leadership Will Drive Long-Term Cash Flow Upside
Analysts have raised their fair value estimate for Adaptive Biotechnologies from approximately $15 to $21 per share. They cite higher long term profit margin expectations and confidence in the company’s leadership in minimal residual disease cancer testing, even with moderating revenue growth assumptions and a higher discount rate.내러티브 업데이트 • Nov 30
ADPT: Future Revenue Will Be Sustained By Leadership In Cancer Testing
Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.내러티브 업데이트 • Nov 16
ADPT: Future Revenue Will Be Driven By Market Expansion In Blood Cancer Testing
Analysts have raised their price target for Adaptive Biotechnologies by $2.00 to $19.14, citing the company's leadership in minimal residual disease testing, as well as expectations for sustained revenue growth and improved margins. Analyst Commentary Recent analyst discussions reveal diverse perspectives on Adaptive Biotechnologies' position in the market and future prospects.내러티브 업데이트 • Nov 01
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
Analysts have increased their price target for Adaptive Biotechnologies from $16.00 to $17.14 per share. They cite continuing leadership in cancer testing and expectations for robust revenue growth, driven by market expansion and operational improvements.내러티브 업데이트 • Oct 18
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.분석 기사 • Oct 16
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 31% gain in the...내러티브 업데이트 • Oct 04
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Analysts have increased their price target for Adaptive Biotechnologies from $14 to approximately $14.86 per share. They cite ongoing revenue growth momentum and strengthening leadership in the cancer diagnostics market as key drivers of the upward revision.분석 기사 • Sep 24
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Aug 29
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 28% Share Price Bounce
Despite an already strong run, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have been powering on, with...내러티브 업데이트 • Aug 07
EMR Integration And Partnerships Will Reshape Clinical Diagnostics
Despite a modest decline in consensus revenue growth forecasts and a slight increase in the discount rate, the consensus analyst price target for Adaptive Biotechnologies has been raised from $11.86 to $13.29. What's in the News Raised full year 2025 MRD business revenue guidance to $190–200 million from the prior $180–190 million range; no revenue guidance for Immune Medicine.분석 기사 • May 31
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 29% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shareholders would be excited to see that the share price has had...분석 기사 • May 07
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Apr 10
Why Investors Shouldn't Be Surprised By Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 26% Share Price Surge
The Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) share price has done very well over the last month, posting an...
새로운 내러티브 • Mar 25
ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines
Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth.분석 기사 • Feb 14
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 40% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 40% gain in the...Seeking Alpha • Nov 26
Adaptive Biotechnologies: Making Some Progress
Summary Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driven by clonoSEQ, continues to show significant growth, and the company's balance sheet remains strong. An updated analysis around Adaptive Biotechnologies follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Nov 26
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) P/S Is Still On The Mark Following 25% Share Price Bounce
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have had a really impressive month, gaining 25% after a...분석 기사 • Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares have continued their recent momentum with a 27% gain in the...분석 기사 • Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
With a median price-to-sales (or "P/S") ratio of close to 3.3x in the Life Sciences industry in the United States, you...분석 기사 • May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) shares are down a...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$50m |
| Dec 31 2025 | US$9m | US$698k | -US$59m |
| Sep 30 2025 | n/a | n/a | -US$80m |
| Jun 30 2025 | n/a | n/a | -US$121m |
| Mar 31 2025 | n/a | n/a | -US$142m |
| Dec 31 2024 | US$5m | US$678k | -US$159m |
| Sep 30 2024 | n/a | n/a | -US$195m |
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
보상 대 시장: Chad의 총 보수(USD9.08M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.53M)보다 높습니다.
보상과 수익: Chad의 보상은 회사가 적자임에도 증가했습니다.
CEO
Chad Robins (50 yo)
16.7yrs
재임 기간
US$9,081,690
보수
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 16.7yrs | US$9.08m | 0.95% $ 21.2m | |
| President & COO | 8.3yrs | US$4.60m | 0.24% $ 5.3m | |
| Co-Founder & Chief Scientific Officer | 16.7yrs | US$8.51m | 0.94% $ 21.1m | |
| VP, CFO & Principal Accounting Officer | 4.6yrs | US$3.31m | 0.030% $ 669.6k | |
| Chief Commercial Officer of MRD | 5.8yrs | US$3.55m | 0.084% $ 1.9m | |
| Founder | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Head of Legal | no data | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 7yrs | 데이터 없음 | 0.17% $ 3.8m | |
| Chief Commercial Officer of Immune Medicine | 8.3yrs | US$1.80m | 0.17% $ 3.8m | |
| Senior Vice President of MRD BioPharma | 2.7yrs | 데이터 없음 | 데이터 없음 |
7.6yrs
평균 재임 기간
50yo
평균 나이
경험이 풍부한 관리: ADPT의 경영진은 노련하고 경험이 풍부합니다(평균 재임 7.6 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 16.7yrs | US$9.08m | 0.95% $ 21.2m | |
| Lead Independent Director | 12.4yrs | US$355.00k | 0.14% $ 3.1m | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 7.2yrs | US$330.00k | 0% $ 0 | |
| Independent Director | 13.3yrs | US$325.00k | 0.029% $ 652.2k | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Corporate Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.2yrs | US$310.00k | 0.045% $ 1.0m |
12.4yrs
평균 재임 기간
60yo
평균 나이
경험이 풍부한 이사회: ADPT의 이사회는 노련하고 경험이 풍부합니다(평균 재임 12.4 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 02:46 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Adaptive Biotechnologies Corporation는 13명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |